01
Treatment and prevention of acute pancreatitis
DISRUPTIVE TECHNOLOGY ADDRESSING UNMET NEEDS IN DIAGNOSIS AND TREATMENT OF LIFE-THREATENING CONDITIONS OF GASTROINTESTINAL, PANCREATO-BILIARY AND OTHER ORGANS AND SYSTEMS
Why we exist
Despite major progress made in diagnosis and treatment of many diseases, there are conditions that have not seen much innovation and improvement in treatment outcomes over the last few decades, despite causing considerable morbidity and mortality and affecting millions of people. Among these are serious conditions of gastrointestinal (GI) and pancreato-biliary systems, such as acute pancreatitis, defects and trauma of GI tract and GI bleeding.
At PANDICA we have developed a range of novel devices, PandiCath®, which, thanks to their versatility, help to address multiple unmet needs in diagnosis and treatment of life-threatening conditions of GI and pancreato-biliary systems. The unique feature of the devices is their ability to create an isolated area with controlled conditions (e.g. active decompression) in GI tract, but at the same time to maintain its connectivity and stimulate its function. This concept of "connects while isolating" enables prolonged use of the devices, essential for their many diagnostic and treatment applications. Application of treatment methods based on the use of PandiCath® will help save thousands of lives, reduce severity of the disease and cost of treating patients.
Applications
Treatment and prevention of acute pancreatitis
Treatment of fistulas, anastomotic leaks, defects and trauma of gastrointestinal tract
Treatment of intraluminal gastrointestinal bleeding
Clinical evidence
Preliminary results of the PoC study suggest significant reduction in the incidence of infectious and non-infectious complications and persistence of MODS in patients treated with HORPIDEN method. Detailed analysis of the study data is underway.
A randomized, controlled, stratified, prospective, open-label, multicenter clinical study has been performed in order to evaluate effectiveness and safety of PandiCath® in combination with Standard of Care vs. Standard of Care alone in treating patients with moderate and severe acute pancreatitis.
The study has completed enrollment of patients in June 2023. Currently the data produced by the study is being reviewed and analyzed with preliminary results suggesting significant improvement of clinical outcomes for patients treated with PandiCath®.
For more details of the study design, conduct and preliminary results please contact us at info@pandica.com.
To Partners
We are looking for collaboration opportunities with investigators, research and clinical organizations who could be interested in exploring the benefits of using our technology and solutions to address their clinical and research needs. For more information or to discuss potential collaboration please contact us at info@pandica.com.
To Investors
We developed a range of fully functional devices with unique characteristics, which have undergone clinical evaluation and demonstrated effectiveness and safety. Further clinical validation and implementation of treatment and diagnostic methods enabled by our technology will result in significant clinical and economic benefits. Multiple patent applications have been submitted and in some cases patents already granted, covering the design, functionality and utility of our devices. If you are interested in exploring and developing the potential of our technology to diagnose diseases and treat patients please contact us at info@pandica.com. Here you can find the link the company's presentation.